448 related articles for article (PubMed ID: 36139368)
1. Boosting the Immune Response-Combining Local and Immune Therapy for Prostate Cancer Treatment.
Karwacki J; Kiełbik A; Szlasa W; Sauer N; Kowalczyk K; Krajewski W; Saczko J; Kulbacka J; Szydełko T; Małkiewicz B
Cells; 2022 Sep; 11(18):. PubMed ID: 36139368
[TBL] [Abstract][Full Text] [Related]
2. New treatments for localized prostate cancer.
Marberger M; Carroll PR; Zelefsky MJ; Coleman JA; Hricak H; Scardino PT; Abenhaim LL
Urology; 2008 Dec; 72(6 Suppl):S36-43. PubMed ID: 19095127
[TBL] [Abstract][Full Text] [Related]
3. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
4. [Focal therapy of prostate cancer].
Ganzer R; Franiel T; Köllermann J; Kuru T; Baumunk D; Blana A; Hadaschik B; von Hardenberg J; Henkel T; Köhrmann KU; Liehr UB; Machtens S; Roosen A; Salomon G; Schlemmer HP; Sentker L; Wendler J; Witzsch U; Schostak M
Urologe A; 2017 Oct; 56(10):1335-1346. PubMed ID: 28856386
[TBL] [Abstract][Full Text] [Related]
5. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
6. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
8. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
9. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years?
Hopstaken JS; Bomers JGR; Sedelaar MJP; Valerio M; Fütterer JJ; Rovers MM
Eur Urol; 2022 Jan; 81(1):5-33. PubMed ID: 34489140
[TBL] [Abstract][Full Text] [Related]
10. Prostate Cancer Immunotherapy-Finally in From the Cold?
Runcie KD; Dallos MC
Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
[TBL] [Abstract][Full Text] [Related]
11. The tumor microenvironment and immune responses in prostate cancer patients.
Kwon JTW; Bryant RJ; Parkes EE
Endocr Relat Cancer; 2021 Jul; 28(8):T95-T107. PubMed ID: 34128831
[TBL] [Abstract][Full Text] [Related]
12. Target ablation--image-guided therapy in prostate cancer.
Marien A; Gill I; Ukimura O; Betrouni N; Villers A
Urol Oncol; 2014 Aug; 32(6):912-23. PubMed ID: 24411788
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive review of immunotherapies in prostate cancer.
Maia MC; Hansen AR
Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
[TBL] [Abstract][Full Text] [Related]
14. The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer.
Xu P; Wasielewski LJ; Yang JC; Cai D; Evans CP; Murphy WJ; Liu C
Biomedicines; 2022 Jul; 10(8):. PubMed ID: 35892678
[TBL] [Abstract][Full Text] [Related]
15. Cancer-cell-intrinsic mechanisms shaping the immunosuppressive landscape of prostate cancer.
Zhu Y; Duong L; Lu X; Lu X
Asian J Androl; 2023; 25(2):171-178. PubMed ID: 36367020
[TBL] [Abstract][Full Text] [Related]
16. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
17. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.
Twardowski P; Wong JYC; Pal SK; Maughan BL; Frankel PH; Franklin K; Junqueira M; Prajapati MR; Nachaegari G; Harwood D; Agarwal N
Cancer Treat Res Commun; 2019; 19():100116. PubMed ID: 30682445
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
[TBL] [Abstract][Full Text] [Related]
20. Effect of high-intensity focused ultrasound on human prostate cancer in vivo.
Madersbacher S; Pedevilla M; Vingers L; Susani M; Marberger M
Cancer Res; 1995 Aug; 55(15):3346-51. PubMed ID: 7542168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]